Business
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) DOYLESTOWN,
About this update from Aprea Therapeutics, Inc.
[{"type":"text","content":"Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor)\nDOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced four poster presentations at the American Association of Cancer Research (AACR) Annual Meeting, to take place April 5 to 10, 2024 in San Diego, CA. The posters will cover ATRN-119, Aprea’s novel macrocyclic ATR inhibitor, and APR-1051, its next generation inhibitor of WEE1 kinase. Presentation Details Title:First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterationsPresenterNadeem Q. Mirza, MD, MPHSession Title:First-in-Human Phase I Clinical Trials 2Date and Time:Tuesday Apr 9, 9:00 AM - 12:30 PM PTLocation:Poster Section 48Poster Board Number:23Abstract Presentation Number:CT195 Title:First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumorsPresenterNadeem Q. Mirza, MD, MPHSession Title:First-in-Human Phase I Clinical Trials 2Date and Time:Tuesday Apr 9, 9:00 AM - 12:30 PM PTLocation:Poster Section 48Poster Board Number:24Abstract Presentation Number:CT196 Title:The novel WEE1i, APR-1051, is a potentially well tolerated and effective treatment for cyclin E-overexpressing cancersPresenter:Molly HansbargerSession Category:Experimental and Molecular TherapeuticsSession Title:DNA Damage and Repair SessionDate and Time:Wednesday Apr 10, 9:00 AM - 12:30 PM PTLocation:Poster Section 22Poster Board Number:16Published Abstract Number:7121 Title:Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastomaPresenter:Teresa Lee, Ph.DSession Category:Experimental and Molecular TherapeuticsSession Title:DNA Damage and RepairSession Date and Time:Wednesday Apr 10, 9:00 AM - 12:30 PM PTLocation:Poster Section 22Poster Board Number:12Published Abstract Number:7117 About ApreaAprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead progra...